During the last three months, 11 analysts shared their evaluations of Viridian Therapeutics (NASDAQ:VRDN), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 5 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.18, along with a high estimate of $61.00 and a low estimate of $27.00. This current average reflects an increase of 9.39% from the previous average price target of $36.73.
Interpreting Analyst Ratings: A Closer Look
The standing of Viridian Therapeutics among...
Login or create a forever free account to read this news
Sign up/Log in
